Skip to Main Content

Contact Information

Carl O. Landgren, M.D., Ph.D.

C. Ola Landgren, M.D., Ph.D.

  • Professor
  • Leader of Experimental Therapeutics Program & Leader of Myeloma Service
  • Medicine
Research InterestPage 1
Mechanisms underlying progression from precursor disease to frank malignancy; prognostic factors associated with progression Role of MRD (minimal residual disease) negativity and biological mechanisms associated with MRD status Drug development; identification of novel targets and intervention of residual/refractory disease